Compare Ascendis Pharma A/S (ASND) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs NetEase Inc — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while NetEase Inc trades at $123 (market cap $82.75B). The key difference: NetEase Inc is far larger — about 5× Ascendis Pharma A/S's market cap, and NetEase Inc pays a 2.36% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NTES | |
|---|---|---|
Market Cap | $16.67B | $82.75B |
Sector | Health | Media |
52-Week High | $277.18 | $159.34 |
52-Week Low | $189.74 | $109.26 |
Enterprise Value | $17.04B | $59.05B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NetEase (NTES) trades at $133.41, up 0.9% with bullish technical signals and strong fundamentals. The stock shows robust profitability with 29.84% net margins and 22.12% ROE, supported by consistent revenue growth to $112.63B in 2025. Recent Q1 2026 earnings beat expectations at $2.53 EPS versus $2.19 forecast. Technical analysis indicates bullish momentum with support at $131 and resistance at $135, while analyst consensus remains strongly positive with 82% buy ratings.
Outlook remains favorable given strong cash flow generation ($50.74B operating cash flow) and international expansion potential. Key risks include Chinese regulatory environment and competitive pressures. With attractive valuation at 16.31 P/E and bullish institutional sentiment, NTES presents growth opportunity though investors should monitor earnings consistency and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
